Ruangnapa K, Samransamruajkit R, Namchaisiri J, Pongsanont K, Boonthim K, Deelodejanawong J, Prapphal N
Division of Pediatric Pulmonary and Critical Care, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Perfusion. 2012 Nov;27(6):547-9. doi: 10.1177/0267659112453474. Epub 2012 Jul 16.
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has been indicated in patients with severe refractory respiratory failure from various causes for more than 30 years, even for the small infant.(1) Improved outcome from using ECMO for respiratory failure has been reported worldwide, ranging from 15% to over 50% in recent reviews.(1,2) The rationale of this therapy is to allow time for the lungs to heal, minimizing further lung injury from positive pressure ventilation.(3,4) We describe a case of severe acute respiratory distress syndrome (ARDS) with extensive barotrauma supported by VV-ECMO for 96 days in a resource-limited center. This is likely the longest ECMO support ever reported in a child.
静脉-静脉体外膜肺氧合（VV-ECMO）已被用于治疗各种原因导致的严重难治性呼吸衰竭患者超过30年，甚至包括小婴儿。（1）全世界都有使用ECMO治疗呼吸衰竭后预后改善的报道，近期综述中的改善率在15%至50%以上。（1,2）这种治疗方法的原理是为肺部愈合留出时间，将正压通气造成的进一步肺损伤降至最低。（3,4）我们描述了一例严重急性呼吸窘迫综合征（ARDS）伴广泛气压伤的病例，该病例在资源有限的中心接受VV-ECMO支持达96天。这可能是有报道的儿童接受ECMO支持时间最长的一例。
